Skip to main content
. Author manuscript; available in PMC: 2012 Sep 15.
Published in final edited form as: Clin Cancer Res. 2011 Aug 3;17(18):5945–5952. doi: 10.1158/1078-0432.CCR-11-0970

Figure 3.

Figure 3

Cytotoxic function of VL peptide-specific normal donor CTLs against U266 and primary human B-cell tumor targets. (A) U266 VL peptide-specific (P19, P20, P21, P23, P25, P26, P27, P28, P29) CTLs generated from a normal donor (ND1) lysed U266 myeloma cells but not ARP-1 (HLA A2−, irrelevant Id) or XG-1 (HLA A2+, irrelevant Id) myeloma cell lines. (B) Human tumor-derived VL peptide-specific (L50 and K18) CTLs lysed the respective primary tumor cells: Tumor (CLL1) and Tumor (PL1), but not tumors expressing irrelevant Id: Tumor (control), or autologous patient’s tumor-free PBMC: PBMC(CLL1) and PBMC(PL1).